Investing & Markets

Make better decisions with investing tips, technical analysis, market commentary, and more

Personal Finance

Make more, save more, spend smarter, and keep more of what you earn

Business News

Stock market news & analysis

Home » Archive by Author

Articles by John McCalister

AspenBio Pharma’s AppyScore Test to conclude by March 31 (NASDAQ:APPY)
03/23/2010 – 10:26 am PDT | Comments Off

On February 9, 2010, AspenBio Pharma, Inc. (NASDAQ:APPY), which is a growing bio science company that develops innovative tests and drugs for the betterment of mankind,

Second Interim Results from Phase 3 trial expected by March 31 (NASDAQ:ARIA)
03/23/2010 – 10:26 am PDT | 3 Comments

Oral ridaforolimus is a drug that has been developed and manufactured by ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA). This drug can be used to treat patients who are suffering from “metastatic soft-tissue and bone sarcomas”.

Enrolling of Phase 2(b) participants expected on March 31 (Nasdaq:ALNY)
03/23/2010 – 10:26 am PDT | Comments Off

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) is a biopharmaceutical company that specializes in providing RNA-based treatment. It has a number of innovative products under its pipeline, and the number is increasing with each passing year.

Results from Oral Interferon’s Phase 2 trial expected by March 31 (OTCBB:AMAR)
03/23/2010 – 10:26 am PDT | Comments Off

Oral interferon is a drug that has been discovered and developed by Amarillo Biosciences, Inc. (OTCBB:AMAR). According to the company, the drug can be used to cure people who have been infected with the influenza …

Preclinical study results of Cobalamin expected by March 31, 2010 (OTCBB:ACCP)
03/23/2010 – 10:10 am PDT | Comments Off

Cobalamin™ is a drug delivery system that has been developed and manufactured by Access Pharmaceuticals, Inc. (OTCBB:ACCP).

Action date of XIFAXAN® expected on March 24 (Nasdaq:SLXP)
03/23/2010 – 10:10 am PDT | Comments Off

On August 24, 2009, Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) disclosed that the FDA had found that the new drug application (NDA) – that was submitted for the company’s recently developed rifaximin tablets 550 mg (called …

Results from LightTouch trials expected to be disclosed on March 24-27 meeting (PINK:GTHP), (OTC:GTHP)
03/23/2010 – 10:09 am PDT | Comments Off

LightTouch™ is a non-invasive medical device that can detect cervical cancer. The device has been developed by Guided Therapeutics, Inc. (PINK and OTC:GTHP.PK). This device is capable of detecting cervical cancer in its early stages …

ODAC meeting with ChemGenex expected on March 22 (ASX:CXS) (Nasdaq:CXSPY)
03/23/2010 – 10:09 am PDT | Comments Off

OMAPRO™ (omacetaxine mepesuccinate) is a drug developed and manufactured by ChemGenex Pharmaceuticals Limited (ASX: CXS).

AstraZeneca’s Esomeprazole PDUFA Date Set For March (NYSE:AZN)
03/15/2010 – 9:48 am PDT | Comments Off
AstraZeneca’s Esomeprazole PDUFA Date Set For March (NYSE:AZN)

A drug containing low aspirin and esomeprazole magnesium has been developed by AstraZeneca (NYSE:AZN), a major pharmaceutical company in the United States, over the last few years. Now the company is planning to bring thris …

PDUFA date of APF530 expected next week (Nasdaq:APPA)
03/11/2010 – 12:56 pm PST | Comments Off
PDUFA date of APF530 expected next week (Nasdaq:APPA)

APF530 is a drug that has been developed by A.P. Pharma Inc. (Nasdaq:APPA) using its “Biochronomer™ polymer-based drug delivery technology”.